RecruitingNCT00923221

Collection of Blood From Patients With Prostate Cancer


Sponsor

National Cancer Institute (NCI)

Enrollment

1,000 participants

Start Date

Feb 28, 2007

Study Type

OBSERVATIONAL

Conditions

Summary

Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene. * Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others. Objectives: -To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state. Eligibility: -All participants participating in NCI prostate cancer protocols. Design: * Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic. * Blood samples are collected at the initial visit or at follow-up visits. * DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines. * Gene variations are correlated with prostate cancer prognosis and prognostic indicators.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria2

  • Individuals 18 years of age and older are eligible.
  • Individuals with a diagnosis of prostate cancer are eligible.

Exclusion Criteria1

  • Children are not eligible.

Locations(1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00923221


Related Trials